Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models

BACKGROUND: Canagliflozin is a sodium glucose co-transporter (SGLT) 2 inhibitor in clinical development for the treatment of type 2 diabetes mellitus (T2DM). METHODS: (14)C-alpha-methylglucoside uptake in Chinese hamster ovary-K cells expressing human, rat, or mouse SGLT2 or SGLT1; (3)H-2-deoxy-d-gl...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Yin, Arakawa, Kenji, Ueta, Kiichiro, Matsushita, Yasuaki, Kuriyama, Chiaki, Martin, Tonya, Du, Fuyong, Liu, Yi, Xu, June, Conway, Bruce, Conway, Jamie, Polidori, David, Ways, Kirk, Demarest, Keith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280264/
https://www.ncbi.nlm.nih.gov/pubmed/22355316
http://dx.doi.org/10.1371/journal.pone.0030555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280264/
https://www.ncbi.nlm.nih.gov/pubmed/22355316
http://dx.doi.org/10.1371/journal.pone.0030555

Ejemplares similares